Literature DB >> 21526065

Does early-onset multiple sclerosis differ from adult-onset form in Iranian people.

Fereshteh Ashtari1, Vahid Shaygannejad, Ziba Farajzadegan, Ali Amin.   

Abstract

BACKGROUND: Few studies have attempted to delineate the clinical profile of multiple Sclerosis (MS) among people of Asia. This study sought to identify the characteristics of early-onset Multiple Sclerosis (EOMS) comparison to adult-onset form (AOMS) in Isfahan, IRAN.
METHODS: This prospective study was conducted on 104 youths with multiple sclerosis beginning before the age of 16 years and 123 patients with adult-onset multiple sclerosis. Patients were observed for a mean period of 5 years. The common presenting symptoms, MRI finding, course of disease and disability score were compared between the two groups.
RESULTS: The mean onset age of disease in youths and adults were 14 ± 1.9 and 27.7 ± 8.06 years, respectively. Female/male ratio was 4.47:1 in EOMS and 3.92:1 in AOMS, this ratio was 7:1 in early childhood MS (≤ 10 year). The most common presenting symptom was optic neuritis in the EOMS group and paresthesia in AOMS. Optic neuritis was common in AOMS too, but brainstem/cerebellar signs were more common in EOMS than AOMS. Seizure occurred more frequently in EOMS than in the AOMS group (12.6% vs. 1.6%, respectively, p < 0.001). MRI showed that brainstem plaques were more prevalent in the EOMS compared with the AOMS group.
CONCLUSIONS: It was concluded that early-onset MS does not significantly differ from adult form in terms of major clinical manifestation and course of disease, however Seizure is more common in EOMS, and brainstem and cerebellar symptoms as presenting symptom are more common.

Entities:  

Keywords:  Adulthood; Multiple Sclerosis; Optic Neuritis

Year:  2010        PMID: 21526065      PMCID: PMC3082796     

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


Multiple Sclerosis (MS) is a chronic inflammatory demylinating and disabling disease, which primarily affect young adults between 20 and 40 years of age. In 0.4% to 10.5% of cases, onset occurs in childhood (before the age of 16 years).12 Although the onset of MS in childhood is recognized worldwide, several barriers exist to its prompt diagnosis in children.3 Many clinicians consider MS as an exclusively adult-onset disease. Therefore, they may not suggest such diagnosis in a child. Moreover, the clinical and radiographic diagnostic criteria for MS have not been validated clearly in the pediatric age group.4 As a result of variability of the clinical features and course and long term prognosis of early onset multiple sclerosis (EOMS), sometimes there is delay in diagnose and therapy of young patients.56 Natural history studies provide important information about MS course and prognosis that might help in treatment approaches.78 However, prognosis of MS according to its age of onset remains controversial. Some researchers reported better outcome in EOMS, whereas others found more favorable prognosis in AOMS than EOMS.9 It is suggested that although the course of MS might be slower in children compared to adults, significant disability may be accumulated in early adulthood and the patient will be disabled at a younger age.10 Nevertheless, some researchers found no influence of age of onset on the prognosis.11 Considering the importance of early treatment of MS in adult, the necessity of understanding the natural history of EOMS becomes more evident.12 In addition, understanding the differences between MS in children and adults is helpful, since research findings in adults could be extrapolated to children and teenagers. The objective of this survey was to highlight the clinical and demographic features of EOMS in Isfahan, Iran and to compare the clinical and paraclinical features of EOMS with adult onset MS (AOMS).

Methods

The sample of this study consisted of 106 MS patients in whom the first attack occurred before the age of 16 years. Simultaneously 130 clinically definite MS patients with adult onset disease and about same duration of disease randomly allocated from Isfahan MS clinics. Diagnosis of MS was confirmed by two neurologists according to McDonald criteria.13 Patients were monitored from January 2000 to August 2006 through routine clinical visits and regular telephone interviews. All patients underwent brain MRI with field strengths of 1.0 Tesla superconductive system. Axial, sagittal, and coronal, T1-weighted, T2-weighted, fluid attenuated inversion recovery (FLAIR), and proton density sequence imaging were performed. MRI findings were analyzed by the Barkhof’s criteria.14 Two patients in EOMS and seven in AOMS were excluded from the study because follow-up was ceased.

Data Collection

A clinical reporting form was designed for every patient and was used in the follow-up course. The baseline data included familial MS history, age, sex and detailed clinical and MRI characteristics, seizure, and amount of disabilities in the beginning and after 5 years follow-up according to Kurtzke’s Expanded Disability Status Scale (EDSS),15 which was detected at least by two neurologists. Certain laboratory tests such as measurement of serum antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies (ANCA), antiphospholipids and anticardiolipin IgG and IgM antibodies, lupus anticoagulant were performed for all of patients to rule out common differential diagnosis of MS. All MRI scans were reviewed by observers blinded to the clinical course. The data collected for disease course included the characteristics of subsequent attacks and occurrence of any disability. Data were obtained directly from the medical records kept by the neurologists. The mean duration of follow up was 4.9 years in EOMS patients and 5.1 years in AOMS. Clinical course was classified according to standardized definitions. The Ethics Committee of the Faculty of Medicine and Biomedical Sciences of the Isfahan University of Medical Sciences approved the study.

Statistical Analysis

The demographic and clinical data were stored in a database and were analyzed by SPSS version 11. Qualitative variables were compared using chi square test. Variables with p < 0.05 were considered significant.

Results

Ultimately 227 MS patients were studied, of which, 104 patients had onset-age less than 16 years of age (EOMS) and 123 patients had onset in adult age (AOMS). In total, the mean age at onset was 21.46 ± 9.1 years while it was 27.7 ± 8.06 (range: 19-40 years) in the AOMS group and 14 ± 1.9 (range: 5-16 years) in the EOMS group. In the EOMS group 77.8% showed a clinical onset between 14 to 16 years; in 8 out of 104 patients (7.7%) the disease started at age 10 years or less. The latter group was considered as a true childhood-onset MS. In EOMS group 81.7% (85 patients) and in AOMS group 79.7% (98 patients) were female (p = 0.696) and the female/male ratio was 4.47:1 vs. 3.92:1 in the two groups, respectively. The proportion of girl to boy was 7:1 in childhood-onset MS group, and female predominance was significant. The most frequent clinical course in both MS groups was relapsing-remitting and 83.7% of EOMS and 84.6% of AOMS patients had this type of course (p = 0.85). The most common presenting symptoms in EOMS patients were optic neuritis followed by brainstem/cerebellar symptoms, while they were paresthesia followed by optic neuritis and brainstem/cerebellar involvement in AOMS (Table 1). One of EOMS patient had encephalopathy picture at onset; the disease was repeated approximately 3 months later and was recovered, but after 5 months she had another relapse and got secondary progressive course.
Table 1

The Characteristics of patients in both MS groups

AOMS n = 123EOMS n = 104P value
Mean age of onset27.7 ± 8.0614 ± 1.9
Female/male (ratio)98/25 (3.92/1)85/19 (4.47/1)
Disease course:
 Relapsing-remitting104 (84.6%)87 (83.7%)0.85
 Secondary progressive16 (13.0%)14 (13.5%)0.92
 Primary progressive3 (2.4%)3 (2.9%)0.83
Optic neuritis at onset36 (29.3%)35 (33.7%)0.48
Parasthesias at onset45 (36.6%)15 (15.4%)0.9
Cerebellar/brainstem at onset23 (18.7%)32 (30.8%)0.034
Motor at onset18 (14.6%)15 (14.4%)0.9
 Others at onset (seizure, sphincter symptom)1 (0.8%)4 (3.8%)0.12
EDSS (after 5 years):
 < 3.5104 (84.6%)84 (80.8%)0.46
 ≥ 3.519 (15.4%)20 (19.2%)
MRI finding:
 Periventricular93 (75.6%)77 (74%)0.78
 Cerebellar/brainstem14 (11.4%)18 (17.3%)0.2
Seizure2 (1.6%)13 (12.6%)0.00
The Characteristics of patients in both MS groups Family history was investigated in all MS patients; 8.7% (n = 9 cases) of EOMS and 12.2% (n = 15 cases) of AOMS patients had a positive family history (p = 0.51). None of the cases of childhood MS patients reported a positive family history for MS. In the brain MRI, periventricular plaque was the most frequent finding in both EOMS and AOMS groups. A high number of patients (74% in EOMS vs. 75.6% in AOMS) had periventricular white matter lesion compatible with MS plaques in T2 W and FLAIR imaging, without significant difference (p = 0.78). The most common finding of MRI in childhood-onset MS was also periventricular plaques (75%). Brainstem plaques were more frequent in the EOMS than in AOMS group, but the differences were not significant (17.3% vs. 11.4% respectively, p = 0.2). Seizure occurred more frequently in EOMS than in the AOMS group (12.6% vs. 1.6% respectively, p < 0.001). After 5 years follow up, 80.8 percent of the patients in the EOMS group and 84.6 percent of the patients in the AOMS group had EDSS of less than 3.5 with no significant difference (p = 0.46). One case of EOMS died after two years.

Discussion

The present study showed that although, EOMS is less common, but it does not differ significantly from AOMS. However, some EOMS aspects are peculiar. In the present series, the youngest age-onset was 5 years. The youngest known patient with MS was a 24 months old child reported by Bejar in 1984.16 It is well documented that MS is more common in women than men. According to the results of this study, the female/male ratio in the EOMS was 4.47:1 and in AOMS was 3.92:1, and 7:1 in childhood MS. These ratios are higher than many other studies, such as the one in Canada in which female to male ratio in childhood-onset MS was reported 3.2:1,17 and the one in Turkey which reported a ratio of 2.5:1.10 Several authors reported a higher frequency of MS among women especially during puberty age. In the study of Ghezzi et al female/male ratio was 4.7 in EOMS with age 12 years, suggesting role of hormonal changes in triggering MS onset.18 But in the present study, sex ratio in prepubertal period was not lower than pubertal period. So present findings may not support the role of hormonal changes in triggering MS. Although the higher female to male ratio in childhood cases has been documented in some previous studies,1920 the results of Simon et al showed significant male preponderance in the group age of less than 10 years.2 In the present study, the most common initial symptom was optic neuritis in EOMS and paresthesia in AOMS. Brainstem and cerebellar symptoms were significantly more common in EOMS and optic neuritis was common presentation in both groups. These findings agree with previous collaboration studies, which showed brainstem and cerebellar symptoms at onset were more common in EOMS patients.5 On the other hand, in a multicenter study of 125 patients with childhood MS, Duquette et al reported that sensory disturbances were the most common initial manifestation of disease occurring in 26.4% of cases, followed by optic neuritis.19 A cooperative retrospective study of 3375 MS patients (149 cases of EOMS) reported higher frequency of brainstem dysfunction in the EOMS group than in the AOMS group.21 Contrary to present findings, the most common presenting symptoms in Taiwan were limb weakness (62%) and visual disturbance (43%).22 Seizure was reported more frequent in MS patients than in general population and it has occurred in 10% of Indian multiple sclerotic patients.23 Overall seizure occurs in about 5% of children with MS, but it is much more common in children under age of 10 years.32425 In the present study, 12.6% of EOMS had seizure that occurred in first two years of disease and 1.6% of AOMS had also seizure (p = 0.001). All of the patients had good prognosis and seizure was controlled completely by one antiepileptic drug, as in Striano et al study.25 Consistent with previous studies in EOMS, the clinical course was predominantly Relapsing-Remitting form (83.7%) and only 2.9% had primary progressive course.19 The family history was positive in 8.7% of EOMS and 12.2% of AOMS in the present study, while it was 13.2% in the study of Ozakbas et al.11 Periventricular plaques were common MRI findings in both groups, as it was in previous study and 90% of EOMS patients fulfilled Barkof’s criteria of MS. But brainstem plaques were more frequent in EOMS, which may explain more common brainstem finding in them. There are several studies about the prognosis of EOMS patients.26 According to these studies after a long period of time from onset of the disease, clinical disabilities in EOMS are less than in AOMS, but ultimately clinical disabilities in EOMS reach a high degree in younger ages compared to the patients in the AOMS groups.121 The results of the present study showed no differences of disabilities in the two groups but a longer follow-up is necessary to decide about this point.

Conclusions

The findings of this study suggest that EOMS should be similar to AOMS in many aspects but there are some differences such as more Brainstem/cerebellar signs at presentation and more seizure in course of disease, so paying attention to these symptoms is important.
  23 in total

1.  Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features.

Authors:  Serkan Ozakbas; Egemen Idiman; Baris Baklan; Burak Yulug
Journal:  Brain Dev       Date:  2003-06       Impact factor: 1.961

2.  Clinical characteristics and long term prognosis in early onset multiple sclerosis.

Authors:  Olivier Deryck; Pierre Ketelaer; Bénédicte Dubois
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

Review 3.  Clinical features of children and adolescents with multiple sclerosis.

Authors:  J M Ness; D Chabas; A D Sadovnick; D Pohl; B Banwell; B Weinstock-Guttman
Journal:  Neurology       Date:  2007-04-17       Impact factor: 9.910

4.  Gait and balance impairment in early multiple sclerosis in the absence of clinical disability.

Authors:  C L Martin; B A Phillips; T J Kilpatrick; H Butzkueven; N Tubridy; E McDonald; M P Galea
Journal:  Mult Scler       Date:  2006-10       Impact factor: 6.312

5.  Multiple sclerosis in childhood: clinical profile in 125 patients.

Authors:  P Duquette; T J Murray; J Pleines; G C Ebers; D Sadovnick; P Weldon; S Warren; D W Paty; A Upton; W Hader
Journal:  J Pediatr       Date:  1987-09       Impact factor: 4.406

Review 6.  Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions.

Authors:  Brenda Banwell; Angelo Ghezzi; Amit Bar-Or; Yann Mikaeloff; Marc Tardieu
Journal:  Lancet Neurol       Date:  2007-10       Impact factor: 44.182

7.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

8.  Epileptic seizures in multiple sclerosis: clinical and EEG correlations.

Authors:  P Striano; G Orefice; V Brescia Morra; P Boccella; C Sarappa; R Lanzillo; G Vacca; S Striano
Journal:  Neurol Sci       Date:  2003-12       Impact factor: 3.307

9.  Natural history of multiple sclerosis with childhood onset.

Authors:  Christel Renoux; Sandra Vukusic; Yann Mikaeloff; Gilles Edan; Michel Clanet; Bénédicte Dubois; Marc Debouverie; Bruno Brochet; Christine Lebrun-Frenay; Jean Pelletier; Thibault Moreau; Catherine Lubetzki; Patrick Vermersch; Etienne Roullet; Laurent Magy; Marc Tardieu; Samy Suissa; Christian Confavreux
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

10.  Sex ratio of multiple sclerosis in Canada: a longitudinal study.

Authors:  Sarah-Michelle Orton; Blanca M Herrera; Irene M Yee; William Valdar; Sreeram V Ramagopalan; A Dessa Sadovnick; George C Ebers
Journal:  Lancet Neurol       Date:  2006-11       Impact factor: 44.182

View more
  7 in total

1.  Characteristics of Children and Adolescents With Multiple Sclerosis.

Authors:  Anita L Belman; Lauren B Krupp; Cody S Olsen; John W Rose; Greg Aaen; Leslie Benson; Tanuja Chitnis; Mark Gorman; Jennifer Graves; Yolander Harris; Tim Lotze; Jayne Ness; Moses Rodriguez; Jan-Mendelt Tillema; Emmanuelle Waubant; Bianca Weinstock-Guttman; T Charles Casper
Journal:  Pediatrics       Date:  2016-07       Impact factor: 7.124

2.  The effect of electronic education on knowledge of patients with multiple sclerosis.

Authors:  Soheila Mohamadirizi; Vahid Shaygannejad; Shahla Mohamadirizi; Zahra Tolou-Ghamari
Journal:  J Educ Health Promot       Date:  2017-04-19

Review 3.  Cerebellar and/or Brainstem Lesions Indicate Poor Prognosis in Multiple Sclerosis: A Systematic Review.

Authors:  Yuyuan Yang; Meng Wang; Lulu Xu; Meixiang Zhong; Yajuan Wang; Moxin Luan; Xingao Li; Xueping Zheng
Journal:  Front Neurol       Date:  2022-04-29       Impact factor: 4.003

4.  Preliminary study related the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the isfahan kashani hospital.

Authors:  Zahra Tolou-Ghamari; Vahid Shaygannejad; Fereshteh Ashtari
Journal:  Int J Prev Med       Date:  2013-05

5.  What is the Real Fate of Vitamin D in Multiple Sclerosis?

Authors:  Vahid Shaygannejad; Zahra Tolou-Ghamari
Journal:  Int J Prev Med       Date:  2013-05

6.  Polymerase chain reaction amplification of a GC rich region by adding 1,2 propanediol.

Authors:  Zeinab Mousavian; Hamid Mir Mohammad Sadeghi; Ali Mohammad Sabzghabaee; Fatemeh Moazen
Journal:  Adv Biomed Res       Date:  2014-01-27

7.  Optic neuritis, the most common initial presenting manifestation of multiple sclerosis in northern Iran.

Authors:  Seyed Mohammad Masoud Hojjati; Amin Zarghami; Seyed Ali Hojjati; Mobina Baes
Journal:  Caspian J Intern Med       Date:  2015
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.